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Abstract 
Overview: Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the 
underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to 
differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive 
imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for 
contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing 
MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic 
toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the 
development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of 
atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in 
vivo. 
Aim: To develop a range of MRI contrast agents based on superparamagnetic iron oxide nanoparticles (SPIONs), and 
test them in a murine model of advanced atherosclerosis. 
Methods: Nanoparticles of four core sizes were synthesised by thermal decomposition and coated with 
poly(maleicanhydride-alt-1-octadecene) (PMAO), poly(ethyleneimine) (PEI) or alendronate, then characterised for 
core size, hydrodynamic size, surface potential and relaxivity. On the basis of these results, one candidate was 
selected for further studies. In vivo studies using 10 nm PMAO-coated SPIONs were performed in ApoE-/- mice fed a 
western diet and instrumented with a perivascular cuff on the left carotid artery. Control ApoE-/- mice were fed a 
normal chow diet and were not instrumented. Mice were scanned on a 3T MR scanner (Philips Achieva) with the 
novel SPION contrast agent, and an elastin-targeted gadolinium agent that was shown previously to enable 
visualisation of plaque burden. Histological analysis was undertaken to confirm imaging findings through staining for 
macrophages, CX3CL1, elastin, tropoelastin, and iron. 
Results: The lead SPION agent consisted of a 10 nm iron oxide core with poly(maleicanhydride-alt-1-octadecene), 
(-36.21 mV, r2 18.806 mmol-1/s-1). The irregular faceting of the iron oxide core resulted in high relaxivity and the 
PMAO provided a foundation for further functionalisation on surface -COOH groups. The properties of the contrast 
agent, including the negative surface charge and hydrodynamic size, were designed to maximise circulation time and 
evade rapid clearance through the renal system or phagocytosis. In vitro testing showed that the SPION agent was 
non-toxic. 
In vivo results show that the novel contrast agent accumulates in similar vascular regions to a gadolinium-based 
contrast agent (Gd-ESMA) targeted to elastin, which accumulates in plaque. There was a significant difference in 
SPION signal between the instrumented and the contralateral non-instrumented vessels in diseased mice (p = 0.0411, 
student’s t-test), and between the instrumented diseased vessel and control vessels (p = 0.0043, 0.0022, student’s 
t-test). There was no significant difference between the uptake of either contrast agent between stable and vulnerable 
plaques (p = 0.3225, student’s t-test). Histological verification was used to identify plaques, and Berlin Blue staining 
confirmed the presence of nanoparticle deposits within vulnerable plaques and co-localisation with macrophages. 
Conclusion: This work presents a new MRI contrast agent for atherosclerosis which uses an under-explored surface 
ligand, demonstrating promising properties for in vivo behaviour, is still in circulation 24 hours post-injection with 
limited liver uptake, and shows good accumulation in a murine plaque model. 
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Introduction 
Cardiovascular disease (CVD), including 
myocardial infarction and stroke, remains a leading 
cause of death and long-term disability worldwide 
[2], costing the UK in excess of €26 billion per year to 
treat [3]. The high mortality is mainly caused by 
coronary atherosclerosis and the high morbidity by 
carotid atherosclerosis and associated stroke. 
Atherosclerosis is a chronic, inflammatory, lipid- 
driven disease of the artery walls. Atherosclerotic 
plaques are classified in a variety of ways and here we 
adopt the simple difference between vulnerable and 
stable plaques, which is based on their propensity to 
rupture with ensuing thrombosis that might occlude 
the lumen. 
A major challenge for medical imaging is the 
development of a contrast agent which can 
differentiate between vulnerable and stable plaques, 
to identify rupture-prone lesions and perhaps to 
enable treatment to trigger plaque stabilisation or 
regression and prevent subsequent cardiovascular 
events. This is particularly important given the 
asymptomatic nature of vulnerable plaque, and the 
low survival rates for out-of-hospital cardiac arrests 
(as measured by patients subsequently discharged 
alive from hospital) remaining below 10% [3]. 
The current gold-standard for human 
atherosclerosis imaging is Optical Coherence 
Tomography (OCT) which can differentiate between 
plaque phenotypes, but which is an invasive 
technique. Computer tomography has also shown 
great promise in vulnerable plaque detection but 
exposes patients to inonizing radiation and thus is not 
ideal for repeat exams [4]. 
Magnetic Resonance Imaging (MRI) is a 
non-invasive imaging technique with excellent 
resolution which does not use ionising radiation to 
generate excellent soft tissue contrast. To further 
enhance contrast between normal and diseased 
tissues, or to obtain molecular and cellular 
information, MR contrast agents can be used. By far 
the majority of MRI contrast agents are based on 
gadolinium-chelates which generate positive T1 
contrast through paramagnetism. However, 
increasingly, alternatives to gadolinium are being 
sought due to toxicity concerns particularly in 
patients with kidney disease, and recent studies 
which have found gadolinium deposits in patients’ 
brains [1,5,6]. 
Commercial, off-the-shelf, non-targeted SPIONs 
have been previously used to image atherosclerotic 
plaques in patients [7,8]. Whilst these studies indicate 
that SPIONs successfully image atherosclerotic 
plaques, the exact correlation with plaque phenotype 
is less clear. 
The aim of this study was to develop a range of 
MRI contrast agents based on superparamagnetic iron 
oxide nanoparticles (SPIONs) with different surface 
functionalisation, and test them in a murine model of 
advanced atherosclerosis to determine whether a 
long-circulating, non-toxic SPION contrast agent 
might offer an alternative to invasive intravascular 
OCT or ultrasound, and to more traditional 
gadolinium-containing MRI contrast agents for the 
detection of vulnerable plaque. 
Results and Discussion 
Contrast agent development 
SPIONs were synthesised using the thermal 
decomposition method first reported by Sun et. al. [9]. 
Four different size cores (6, 8, 10, 12 nm) were grown 
to examine the relationship between core size and 
relaxivity. The hydrophobic particles were phase 
transferred using three different ligand systems, poly 
(maleic anhydride-alt-1-octadecene) (PMAO) [10], 
alendronate [11], and poly(ethyleneimine) (PEI). The 
surface ligands all offered different characteristics, 
comparing encapsulation (PMAO), and ligand 
exchange (alendronate and PEI), different surface 
groups (-COOH and -NH2), as well as newer (PMAO) 
and more established ligands (PEI). 
The nanoparticles were characterised in terms of 
core size, hydrodynamic size, surface charge, and 
relaxivity. Hydrodynamic size and surface charge are 
both important considerations in predicting and 
governing in vivo behaviour. Long circulation times 
allow the contrast agent to accumulate in plaque 
through a combination of phagocytosis by plaque 
macrophages, and the enhanced permeability and 
retention (EPR) effect arising from endothelial 
dysfunction. This would also provide a platform for 
potential targeting of the probe to vulnerable 
plaque-specific proteins such as CX3CL1 [12-16], 
VCAM-1 [17-19], VEGF [20], or αvβ3 integrin [21] 
through antibodies, which require long-circulation to 
be effective targeting moieties. In addition to an 
imaging platform, targeting the probe to chemokines 
such as CX3CL1, CCR2 or CCL5 would have potential 
therapeutic benefits. These chemokines are all 
associated with vulnerable plaque, and blocking their 
expression has been shown to lead to plaque 
stabilisation and regression [15,22]. Developing a 
long-circulating probe targeted to one or multiple of 
these proteins would aid in the detection of 
vulnerable plaque, as well as treating it in situ and 
improving patient outcomes. 
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In order to ensure the long circulation of the 
probe, the clearance route was of primary 
consideration. There is a size window between 6-200 
nm for avoiding renal clearance (<6 nm) [23] and 
clearance immediately through the 
reticuloendothelial system (>200 nm). Core size was 
measured by transmission electron microscopy (TEM) 
(Figure 1) and hydrodynamic size through dynamic 
light scattering (DLS) (Table 1). Surface charge 
particularly affects interaction with the immune 
system, where neutral agents are longer-circulating, 
positively-charged agents clear faster due to higher 
intracellular uptake resulting from the electrostatic 
attraction to the cell membrane, and opsonisation by 
proteins in the blood stream accelerating phagocytosis 
[24-26]. Negatively-charged agents are not as 
long-circulating as neutral agents but are better than 
positively-charged agents for antibody targeting. 
DLS and visual inspection both showed the 
formation of large aggregates with both amine-based 
surface ligands, and PEI in particular, was very 
challenging to exchange onto the nanoparticles 
despite testing multiple conditions. PMAO showed 
much narrower size dispersions and improved 
stability, in water and phosphate buffered saline in 
accordance with literature findings [27]. The 
carboxylic acid groups on the surface of the PMAO- 
coated particles resulted in a negative surface charge, 
and that in combination with the narrower size 
dispersion, lack of aggregation and long-term stability 
made it the most suitable choice for this contrast 
agent. PMAO has also not seen application in vivo yet, 
and the probe is therefore novel in surface 
functionalisation, and looks to be a promising 
platform for many applications. Nanoparticle contrast 
agents are easily tuned to many different targets and 
applications, and -COOH groups are easily 
functionalised with targeting moieties for molecular 
imaging, dyes or fluorophores for optical imaging and 
potentially histology, chelators for radionuclides or 
gadolinium, meaning that this probe has potential 
across a wide spectrum of applications and 
modalities. 
The relaxivity measurements were the decisive 
factor in selecting the lead-candidate for antibody- 
coupling, with the 10 nm nanoparticle cores showing 
the highest r2 (18.806 mmol-1s-1). An anti-CX3CL1 
antibody was coupled to the surface of the probe 
through carbodiimide coupling to test the feasibility 
of molecular targeting, and tests indicated that the 
antibody was successfully coupled to the nanoparticle 
surface, and that it retained binding ability after 
coupling. 
In vitro evaluation 
A cell viability assay using RAW 264.7 murine 
macrophages was undertaken to confirm the contrast 
agent was non-toxic. Cells were incubated with 
varying concentrations of iron in excess of what might 
be encountered in vivo, and the SPIONs were 
compared to FeCl3. Cell viability was assessed using a 
standard tetrazolium/formazan cell viability dye 
[2,3-bis-(2-methoxy, 4-nitro, 5-(sulfophenyl)-2H- 
tetrazolium-5-carboxanilide) (XTT)] measured with 
absorbance spectroscopy, by minor modification of 
previous methods [28-32]. Higher measured cell 
survival was observed for those cells treated with 
SPIONs as opposed to FeCl3 at all concentrations, as 
can be observed in Figure 2. For each concentration, 
cell survival was higher for SPIONs than the 
corresponding amount of FeCl3, further evidence that 
the SPIONs were at least as well tolerated as 
unencapsulated Fe. For reference, Fe is measurable in 
peripheral serum at a peak concentration of 
approximately 10 mM after a conventional dietary 
iron supplement [33] (Figure 2). 
 
 
Figure 1. TEM characterisation. (A) Graph showing measured nanoparticle core size versus projected nanoparticle core size. (B) TEM image showing irregular 
faceting of nanoparticle cores. 
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Figure 2. Cell survival assays with SPIONS. Graphs demonstrating measured cell survival of RAW 264.7 murine macrophages at 24 hours incubation with 
varying concentrations of iron in the form of anti-Fractalkine SPIONs or FeCl3. (A) Cell counts using a hemacytometer at 24 hours showing an equivalent and slight 
loss of cells at 24 hours at extreme concentrations (100 µM) of SPIONs and FeCl3. (B) Colorimetric cell survival assay based on formazan (XTT) reduction, also 
carried out at 24 hours and also showing an equivalent slight loss of cells at 24 hours at extreme concentrations (100 µM) of SPIONs, whether targeted or untargeted 
(no antibody). FeCl3 increases apparent cell number, although that is likely to represent an artefact e.g. mitochondrial dysfunction. Data were also obtained at 2 hours, 
when there was very little effect (not shown). 
 
Table 1. Hydrodynamic size and surface potential measurements 
for all synthesised nanoparticles 
Sample Diameter in nm Potential in mV 
6 nm iron oxide with PEI 148.5 3.30 
8 nm iron oxide with PEI 206.5 1.60 
10 nm iron oxide with PEI --- 10.91 
12 nm iron oxide with PEI 371.5 5.73 
6 nm iron oxide with PMAO 113.2 -42.11 
8 nm iron oxide with PMAO 104.7 -36.66 
10 nm iron oxide with PMAO 194.6 -36.21 
12 nm iron oxide with PMAO 139.6 -22.84 
6 nm iron oxide with alendronate 199.5 26.86 
8 nm iron oxide with alendronate 292.7 12.12 
10 nm iron oxide with alendronate 194.0 26.60 
12 nm iron oxide with alendronate 266.4 28.44 
 
 
Figure 3. Specific binding of anti-factalkine SPIONs to immobilised 
fractalkine shown by Berlin-Blue based iron measurement. Graph 
showing bound as detected by Berlin Blue and UV-Vis. spectroscopy in wells 
coated with CX3CL1 and incubated with targeted and non-targeted SPIONs. 
*p<0.05, ANOVA. 
 
In order to confirm that the anti-fractalkine- 
SPION conjugate specifically targeted fractalkine, a 
binding assay was designed. Both targeted and 
non-targeted SPIONs were incubated against murine 
CX3CL1 or control-coatings on 96-well plates (see 
Methods). To obtain an unambiguous demonstration 
that iron-containing particles were captured by plate- 
adsorbed fractalkine, unbound particles were 
removed through a gentle wash and plate-bound iron 
detected a reaction product with Berlin Blue (acidified 
potassium ferricyanide, a classical reagent for 
detecting immobilized iron) added. After 10-20 mins 
incubation, Berlin Blue/iron complex was measured 
by UV-Vis. spectroscopy. The results (Figure 3) 
demonstrated higher levels of bound iron detected in 
the wells with targeted SPIONs as opposed to control 
SPIONs. 
In vivo evaluation 
The contrast agent was tested in a murine model 
of advanced (vulnerable) plaque: 6 ApoE-/- C57/Bl6 
female mice fed a high fat diet with a cuff placed on 
the left carotid artery for 9 weeks to cause a stenosis 
and changes in wall shear stress patterns. The model 
was developed to cause a vulnerable plaque upstream 
of the cuff and a stable plaque downstream of the cuff, 
which made it particularly suitable for testing this 
contrast agent by enabling the direct comparison of 
uptake in known vulnerable and stable plaque sites 
[34]. 
The mice were first injected with a 
gadolinium-containing elastin-specific MR contrast 
agent (Gd-ESMA) which has been characterised in 
atherosclerosis models, allowed to visualise the 
location and extend of plaque and provided a 
benchmark for the novel contrast agent. The mice 
were then injected with the SPIONs and imaged 24 
hours post-injection. The results are illustrated in 
Figures 4 and 5. 
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Figure 4. Top to bottom, (A) Left: graph showing lumen area versus slice number, demonstrating a consistent decrease in lumen area from slice 3-5 (standardised 
relative to aortic arch) in all 6 animals (represented by different legends) corresponding to cuff location; right: anatomical scan showing the location of the cuff and 
resulting arterial stenosis; (B) Left: Magnetic Resonance Angiography scan (Top) showing the brachiocephalic artery, left carotid artery, and left subclavian artery 
(L-R), Bottom: Inversion recovery image showing plaque areas with Late Gadolinium enhancement from Gd-ESMA in the vessel walls. Right: Image overlay showing 
the areas of enhancement in relation to the vessel lumen. (C) Two examples of T2* echo scans based on the protocol from Makowski et. al. [35] showing negative 
contrast areas in the vessel walls. 
 
The Gd-ESMA scans showed a significant 
difference between uptake in the cuffed vessel 
compared with the contralateral control vessel (p = 
0.018), demonstrating that the cuff placement and 
hyperlipidemia led to the formation of plaque more 
rapidly than hyperlipidemia alone through alterations 
of wall shear stress. There was also a significant 
difference between the Gd-ESMA signal in the cuffed 
disease vessel compared to both the left and right 
carotid arteries in the control animals ((p = 0.002, 
0.000095), supporting the plaque formation as a result 
of hyperlipidemia and placement of the cuff with 
resultant stenosis (Figure 5). The data was analysed 
using multiple non-parametric t-tests corrected for 
multiple comparisons by the Holm-Sidak method, 
and was found to be statistically significant. There 
was no notable difference in Gd-ESMA signal 
between the stable and vulnerable plaque regions 
measured in three slices above and below the stenosis 
of the cuff, but it was not expected that elastin content 
would differ significantly, particularly given that 
Gd-ESMA binds to both the cross-linked mature form 
of elastin, and its precursor tropoelastin. Interestingly, 
the brachiocephalic artery was observed to be 
enlarged related to other murine atherosclerosis 
models, and this is likely to be a result of 
compensation due to the restriction the cuff places on 
the left carotid. 
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Figure 5. (A) Graph showing plaque volume as measured by area of late-gadolinium enhancement in both the left (LCA) and right (RCA) carotid arteries of control 
(left) and diseased (right) animals, showing that cuff placement and hyperlipidemia increase plaque size in the instrumented diseased left carotid artery (*p<0.05, 
student’s t-test); (B) graph showing plaque volume as measured by T2* enhancement in the left (LCA) and right (RCA) carotid arteries of control (left) and diseased 
(right) animals, showing that cuff placement hyperlipidemia increase plaque size in the instrumented diseased left carotid artery (*p<0.05, student’s t-test); (C) graph 
showing area of void (AOV) arising from SPIONs and area of late-gadolinium enhancement (AOE) arising from Gd-ESMA in control regions pre- (upstream) and 
post-cuff (downstream), although differences are present, no level of significance was reached. 
 
The SPION behavior mirrored Gd-ESMA signal, 
validating the novel contrast agent against an 
established agent to measure plaque burden. Again, 
there was a significant difference between the 
modified vessel and the internal control vessel (p = 
0.018), and between the modified, diseased vessel and 
both vessels in the control animalsp = 0.005, 0.002) 
(Figure 5). The data was analysed using multiple non- 
parametric t-tests corrected for multiple comparisons 
by the Holm-Sidak method, and was found to be 
statistically significant. 
There was no significant difference between the 
uptake of either contrast agent between the 
vulnerable plaque upstream of the cuff, and the stable 
plaque downstream of the cuff (p = 0.32, student’s 
t-test) (Figure 5). 
Histological verification 
Imaged plaques and control sections of artery 
were then analysed through histology and 
immunohistochemistry, staining sections for elastin, 
tropoelastin, CD68, CX3CL1 (a marker for vulnerable 
plaque), and iron. Berlin blue staining for iron 
confirmed the presence of SPION-derived iron in the 
plaques of diseased vessels (Figure 8), but there was 
no Berlin blue staining in the control vessels. There 
was a significant difference in expression of both 
CD68 which is a macrophage marker, and Fractalkine 
between sections of tissue from diseased and healthy 
control animals. Levels of tropoelastin were also 
elevated in plaque regions. These findings are 
illustrated in Figures 6 and 7. 
Conclusions 
In conclusion, this paper illustrates the 
development of a novel superparamagnetic iron oxide 
nanoparticle contrast agent which successfully 
allowed imaging of atherosclerotic plaques with MRI. 
Although the probe is not specific for vulnerable 
plaque, it is non-toxic and accumulates in similar 
regions to an elastin-targeted agent for visualizing 
plaque burden. It also provides a good platform for 
further refinement towards a vulnerable plaque- 
specific contrast agent in the future. The novel probe 
has successfully been labelled with an antibody, and 
the conjugated antibody has been demonstrated to 
retain binding specificity for the target. There is a 
limitation in that the nanoparticles were labelled with 
an anti-CX3CL1 antibody, however this labelling was 
at a low proportion of the injected dose and so the 
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probe has not been treated as a targeted agent. 
Because of this, no conclusions can be drawn 
regarding potential levels of CX3CL1 expression in 
the plaques, although previous work by Cheng et. al. 
suggests that CX3CL1 is elevated in vulnerable 
plaques [11]. 
Methods 
Chemistry 
Synthesis of 6 nm hydrophobic SPIONs [36] 
Fe(acac)3 (0.71 g, 2 mmol) and 1,2-hexa-
decanediol (2.58 g, 10 mmol) were dissolved in benzyl 
ether (20 ml). Oleic acid (2.11 ml, 6 mmol) and 
oleylamine (2.80 ml, 6 mmol) were added, and the 
mixture was stirred for 2 hours under N2 at 200 °C. 
The mixture was then heated to reflux (300 °C) for 1 
hour and cooled by the removal of the heat source.  
Nanoparticles were precipitated with EtOH (40 
ml) and centrifuged for 30 minutes at 4000 rpm. Pellet 
was re-dispersed in hexane (20 ml), centrifuged for 10 
minutes at 4000 rpm and then precipitated again with 
EtOH (20 ml). The solution was centrifuged for 30 
minutes at 4000 rpm, supernatant removed and pellet 
dried under vacuum. SPIONs were stored dry. 
Seed-mediated growth of SPIONs [36] 
Fe(acac)3 (0.18 g, 0.5 mmol) and 
1,2-hexadecanediol (0.65 g, 2.5 mmol) were dissolved 
in benzyl ether (15 ml). Oleic acid (0.70 ml, 0.5 mmol), 
oleylamine (0.93 ml, 0.5 mmol) and SPIONs (5-10 mg) 
were added and the mixture was stirred for 1 hour at 
200 °C. The mixture was then heated to reflux (300 °C) 
for half an hour and cooled by the removal of the heat 
source. 
The workup was performed as with 6 nm 
hydrophobic SPIONs. 
Coating with poly(maleic anhydride-alt-1-octadecene) 
[10] 
Poly(maleic anhydride-alt-1-octadecene) 
(PMAO) (45 mg) was dissolved in CHCl3 (20 ml). The 
SPIONs (2 mg) were added and mixture was stirred 
for 30 minutes. Chloroform was removed, and residue 
re-dissolved in a small amount of CHCl3. NaOH (aq) 
(0.05 M) was added and mixture was heated at 60 °C 
until SPIONs transferred to the aqueous phase. 
 
 
 
Figure 6. From top to bottom and left to right: (A) Graph illustrating the percentage vessel wall area of CX3CL1 measured in diseased and control sections; (B) 
Graph illustrating the percentage vessel wall area of CD68 measured in diseased and control sections; (C) Graph illustrating the plaque area measured in diseased and 
control sections; (D) Graph illustrating the percentage vessel wall area of tropoelastin measured in diseased and control sections. 
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Figure 7. (A) Section of control vessel stained for elastin and, (B) section of diseased vessel stained for elastin showing a plaque. (C-D) Sections of diseased vessel 
stained for tropoelastin, showing a plaque. (E) Section of diseased vessel showing a plaque stained for CD68, and (F) section of diseased vessel showing a plaque 
stained for CX3CL1. 
 
The solution was filtered using on a 0.45 µm 
filter, and then concentrated by centrifugation with a 
filter of 30k Mw. Particles were re-suspended in water 
and stored. 
Coating with alendronate [11] 
Sodium alendronate trihydrate (50 mg) was 
dissolved in water (5 ml) adjusted to pH 9 with 1 M 
KOH. The SPIONs (6 mg) were suspended in THF. 
The solutions were combined and stirred at room 
temperature for 2 days. The solution was magnetically 
decanted and washed with acetone (3 × 10 ml). The 
particles were re-suspended in water and stored. 
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Figure 8. Examples of sections stained for iron with Berlin Blue, highlighting the 
blue deposits in plaque regions. 
 
Biology 
In vitro cell toxicity assay 
Preparation of XTT working reagent: 
5 ml of PBS (Phosphate Buffered Saline) and 50 
µl of XTT (25 mg/ml) and 0.5 µl PMS (Phenazine 
methosulfate, 50 mg/ml) was added into a clean 15 ml 
conical centrifuge tube. 
In a 96 well plate each well was seeded with 200 
µl of 10k RAW 264.7 cells in IMDM with 10% FBS. The 
plate was incubated overnight, and then treated with 
SPIONs at different concentrations: 0 µM, 1 µM, 10 
µM and 100 µM. The plate was incubated overnight, 
and 20 µl of XTT reagent as prepared above was 
added to the wells and incubated. The absorbance 
was measured at 2 and 24 hours post-addition of XTT 
at 450 and 540 nm. 
Animal Model 
All animal experiments complied with the 
Animals (Scientific Procedures) Act 1986 and were 
carried out under PPL 70/8482 at King’s College 
London. 
Homozygous female ApoE-/- mice (C57BL/6J 
background) were acquired from Charles Rivers 
Laboratories (Edinburgh, UK) and bred within the 
Behavioural Sciences Unit of the Rayne Institute. The 
housing and care of the animals, and all procedures in 
this study were performed in accordance with the 
guidelines and regulations of the UK home office. 
At 11 weeks of age the mice were placed on high 
fat diet (HFD) (21% fat, 0.25% cholesterol wt/wt from 
LBS-Biotech) for two weeks prior to surgery. Two 
weeks after commencement of HFD the mice 
underwent surgery for the placement of a rigid 
polyether ketone perivascular cuff (Promolding, The 
Netherlands) around the left carotid. The cuff was 
supplied in two pieces and when assembled the 
lumen narrowed from 500 µm to 250 µm over 1.5 mm. 
The animals were kept under anaesthesia at 1.5-2.5% 
isoflurane and 2% O2, with anaesthetic depth being 
assessed from respiratory rate, hind limb muscle tone, 
and pedal withdrawal reflex as previously described 
[34]. 
The animals then remained on HFD for a further 
9 weeks before scanning and sacrifice. Animals were 
euthanised under Schedule 1 with an overdose of 
anaesthetic followed by exsanguination and flushing 
of the vasculature with saline. 
Healthy ApoE-/- mice with no cuff fed a normal 
chow diet were used as controls. 
Imaging Studies: Gd-ESMA 
Based on previous studies carried out by 
Makowski et. al. [37] animals were injected with 0.2 
mmol/kg Gd-ESMA in 150 µl sterile saline through 
the tail vein. The animals were then scanned 1 hour 
post-injection. 
In vivo vessel wall imaging was performed using 
a Philips Achieva MR scanner (Philips Healthcare, 
Best, The Netherlands) equipped with a clinical 
gradient system (30 mT m−1, 200 mT m−1 ms−1). 
The brachiocephalic artery (BCA) and left and 
right carotids were imaged using a single-loop surface 
coil (diameter = 23 mm). Mice were placed in prone 
position after intravenous administration of 0.2 
mmol/kg Gd-ESMA (Lantheus Medical Imaging, 
North Billerica, MA). Anesthesia was induced with 
5% and maintained with 1% to 2% isoflurane during 
the MRI experiments. 
After a 3-dimensional gradient recalled echo 
scout scan, contrast-enhanced angiography images 
were acquired with a field of view (FOV) = 30× 30× 8 
mm, matrix = 200× 200, in-plane resolution = 0.15× 
0.15× 0.5 mm (reconstructed = 0.10× 0.10 mm), 
repetition time/echo time = 15/6.1 ms, and flip angle 
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= 40°. The maximum intensity projection images were 
used to plan the subsequent delayed-enhancement 
(DE) and T1 mapping scans. A 2-dimensional 
Look-Locker sequence was acquired using the 
following parameters: FOV = 30× 30 mm, matrix = 
80× 80, in-plane resolution = 0.38× 0.38× 2 mm, 
repetition time/echo time = 19/8.6 ms, repetition time 
between subsequent inversion recovery pulses = 1000 
ms, and flip angle = 10°. An inversion recovery 
3-dimensional fast gradient echo sequence was 
acquired with FOV = 30× 30× 8 mm, matrix = 304× 
304, in-plane resolution = 0.1× 0.1× 0.5 mm, repetition 
time/echo time = 28/8 ms, repetition time between 
subsequent inversion recovery pulses = 1000 ms, and 
flip angle = 30°. T1 mapping was performed with the 
same sequence employed for the aorta. The 
acquisition parameters were as follows: FOV = 36× 
22× 8 mm, matrix = 192× 102, in-plane resolution = 
0.18× 0.22× 0.5 mm, slices = 16, repetition time/echo 
time = 9.6/4.9 ms, flip angle = 10°. 
Imaging Studies: SPIONs 
Animals were injected with 150 µl 6 mM [Fe] 
SPIONs in sterile saline through the tail vein. The 
animals were then scanned 24 hours post-injection. 
The imaging protocols were based on previous 
experiments by Makowski et. al. [35] and were carried 
out on a Phillips 3T Achieva scanner (Philips 
Healthcare, Best, The Netherlands) equipped with a 
clinical gradient system (30 mT m−1, 200 mT m−1 ms−1) 
as before. 
The brachiocephalic artery (BCA) and left and 
right carotids were imaged using a single-loop surface 
coil (diameter=23 mm). Mice were placed in prone 
position. Anesthesia was induced with 5% and 
maintained with 1% to 2% isoflurane during the MRI 
experiments. 
After a 3-dimensional gradient recalled echo 
scout scan, contrast-enhanced angiography images 
were acquired with a field of view (FOV) = 30× 30× 8 
mm, matrix = 200× 200, in-plane resolution = 0.15× 
0.15× 0.5 mm (reconstructed = 0.10× 0.10 mm), 
repetition time/echo time = 15/6.1 ms, and flip angle 
= 40°. The maximum intensity projection images were 
used to plan the subsequent T2*-weighted 3D gradient 
echo scan. ECG-triggering was not used, and a 
T2*-weighted 3D gradient echo data set was acquired 
with FOV = 16× 16× 8; matrix = 176× 176; in-plane 
spatial resolution = 0.12× 0.12 mm; slice thickness = 
0.5 mm; TR/TE = 37.88/7.32 ms and flip angle = 25°. 
Histology 
Elastin Staining 
Deparaffinised slides were incubated in working 
elastic stain solution for 10 minutes and rinsed in 
deionized water. Slides were then placed in ferric 
chloride solution for 22 seconds, rinsed under running 
water and checked under the microscope. Slides were 
rinsed in 96% ethanol to remove excess iodine, then 
rinsed in deionized water. Slides were incubated in 
van Gieson solution for 1-3 minutes. Finally, slides 
were dehydrated through a gradient of ethanol, 
cleared in xylene, and mounted. 
Prussian Blue Staining 
20% aqueous solution of hydrochloric acid (20 
ml conc. HCl, 80 ml water) and 10% potassium 
ferrocyanide trihydrate (10 g, 100 ml water) were 
prepared and mixed fresh before staining. Slides were 
immersed in the solution for 20 minutes then washed 
in deionized water three times before counterstaining 
with nuclear fast red for 5 minutes. Finally, slides 
were dehydrated through a gradient of ethanol, 
cleared in xylene, and mounted. 
Immunohistochemistry 
Deparaffinised slides were stained for tropoelastin, CD68 
or CX3CL1 using the following protocol: 
Endogenous peroxidase was inhibited by 
incubation of the slides in 3% oxygenated water and 
methanol for 10 minutes. Slides were then washed in 
deionized water for 10 minutes. Antigen retrieval was 
performed by boiling the samples for 2 minutes at 110 
°C in citrate buffer in a pressurized antigen retrieval 
unit and then allowed to cool. Samples were washed 
with PBS for 3 minutes, and blocking was performed 
for 1 hour at room temperature with 10% donkey 
serum in PBS. Incubation with the primary antibody 
was carried out overnight at 4 ˚C diluted 1:100 in PBS 
2% normal donkey serum. Samples were allowed to 
temper at room temperature for 1 hour, then slides 
were washed twice in PBS for 20 minutes. Slides were 
incubated with anti-rabbit HRP polymer for 45 
minutes at room temperature then washed 3 times in 
PBS for 5 minutes.  
Slides were revealed with Vector SG Peroxidase 
substrate for 10 minutes at room temperature 
PBS (5 ml), Chromogen (75 μl), Hydrogen peroxide 
(120 μl). 
Samples were washed twice in PBS for 5 
minutes, before counterstaining with nuclear fast red 
for 5 minutes. Slides were washed with deionized 
water then finally dehydrated through a gradient of 
ethanol, cleared in xylene, and mounted. 
Supplementary Material  
Supplementary figure S1. 
http://www.ntno.org/v04p0184s1.pdf  
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